ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 135 • 2012 ACR/ARHP Annual Meeting

    A Pilot Study of the Efficacy of IL1 Blockade by Anakinra in Acute Calcific Periarthritis of the Rotator Cuff

    Pascal Zufferey1, Melanie Faucherre2, Pierre A. Varisco1, Berengere Aubry Sr.1, Isabelle Fabreguet3 and Alexander K. So Sr.1, 1Dal/Rhu, CHUV, Lausanne, Switzerland, 2Dal /Rhu, CHUV, Lausanne, Switzerland, 3CHUV, Lausanne, Switzerland

    Background/Purpose: Calcific periarthritis of rotator cuff can induce acute and severe shoulder pain and is accompnied by signs of acute inflammation.  The calcific deposits are…
  • Abstract Number: 136 • 2012 ACR/ARHP Annual Meeting

    A Delphi Exercise to Identify Characteristic Features of Gout – A Study of Opinions From Patients and Physicians to Inform New Classification Criteria

    Rebecca Prowse1, Nicola Dalbeth2, H. R. Schumacher3, Tuhina Neogi4, Tim L. Jansen5, Jaap Fransen6 and William Taylor1, 1University of Otago, Wellington, New Zealand, 2Medicine, University of Auckland, Auckland, New Zealand, 3Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4Boston University School of Medicine, Boston, MA, 5Rheumatology, St Radboud University Nijmegen Medical Centre, Netherlands, 6Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    A Delphi Exercise to Identify Characteristic Features of Gout - a Study of Opinions from Patients and Physicians to Inform New Classification CriteriaBackground/Purpose: Updated classification…
  • Abstract Number: 137 • 2012 ACR/ARHP Annual Meeting

    Monosodium Urate Crystals Inhibit Tenocyte Viability and Function: Implications for Periarticular Involvement in Chronic Gout

    Ashika Chhana1, Karen E. Callon1, Bregina Pool1, Dorit Naot1, Gregory Gamble2, Brendan Coleman3, Fiona M. McQueen4, Jillian Cornish1 and Nicola Dalbeth1, 1Medicine, University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3Orthopedic Surgery, Middlemore Hospital, Auckland, New Zealand, 4Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand

    Background/Purpose: Recent advanced imaging studies have demonstrated that urate deposition in periarticular structures is common in gout. Urate deposition has been observed both adjacent to…
  • Abstract Number: 138 • 2012 ACR/ARHP Annual Meeting

    Evaluating Appropriate Use of Prophylactic Colchicine and Urate Lowering Therapy in Gout

    Michael George1, Sally W. Pullman-Mooar2 and H. Ralph Schumacher3, 1Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Rheumatology, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, 3Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA

    Background/Purpose: Colchicine is recommended to prevent gout flares in patients initiating and increasing uric acid lowering therapy until serum uric acid is ≤ 6 mg/dL.…
  • Abstract Number: 139 • 2012 ACR/ARHP Annual Meeting

    Lack of Effect of Supplemental Vitamin C On Serum Urate in Patients with Gout

    Lisa K. Stamp1, Christopher Frampton1, John L. O'Donnell2, Jill Drake3 and Peter T. Chapman4, 1Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 2Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, 3Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, 4Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand

    Background/Purpose:   The key to effective long-term management of gout is sustained reduction of serum urate (SU) Methods: Patients with gout and a SU >0.36mmol/L…
  • Abstract Number: 140 • 2012 ACR/ARHP Annual Meeting

    Patients That Continue to Flare Despite Apparent Optimal Urate Lowering Therapy

    Dinesh Khanna1, Puja Khanna2, David Hagerty3, Chris Storgard4, Robert Mischler5 and Robert Morlock5, 1Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 2Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, 3Medical, Ardea Bioscience, San Diego, CA, 44939 Directors Place, Ardea Bioscience, San Diego, CA, 5Ardea Bioscience, San Diego, CA

    Background/Purpose: Gout is a common inflammatory arthritis and its worldwide prevalence is increasing.  The purpose of this study is to describe physician, patient and treatment…
  • Abstract Number: 141 • 2012 ACR/ARHP Annual Meeting

    Effectiveness of Prophylaxis with Anti-Gout Medications On Risk of Gout Attacks

    Tuhina Neogi1, Clara Chen2, Jingbo Niu3, Christine E. Chaisson4, David J. Hunter5, Hyon Choi6 and Yuqing Zhang7, 1Clinical Epidemiology, Boston University School of Medicine, Boston, MA, 2Boston University School of Public Health, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4Arthritis Center, Boston University School of Public Health, Boston, MA, 5Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, 6Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 7Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: While a few studies have examined colchicine's ability to prevent gout attacks, NSAIDs have not been formally studied in this regard, despite use of…
  • Abstract Number: 142 • 2012 ACR/ARHP Annual Meeting

    Efficacy of Canakinumab Versus Triamcinolone Acetonide According to Multiple Gouty Arthritis-Related Health Outcomes Measures

    Ari Gnanasakthy1, Andrew Sarkin2, Rachel Lale2, Kyle Choi2 and Jan D. Hirsch3, 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2Health Services Research Center, University of California, San Diego, CA, 3Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, CA

    Background/Purpose: Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, may be a potential therapeutic option for treating acute gout attacks and delaying new attacks…
  • Abstract Number: 143 • 2012 ACR/ARHP Annual Meeting

    Proposed Gout Treatment Guidelines and Meeting Serum Urate and Flare Goals

    Jasvinder A. Singh1, David Hagerty2, Chris Storgard3, Robert Mischler4 and Robert Morlock4, 1Department of Medicine, University of Alabama, Tuscaloosa, AL, 2Medical, Ardea Bioscience, San Diego, CA, 34939 Directors Place, Ardea Bioscience, San Diego, CA, 4Ardea Bioscience, San Diego, CA

    Background/Purpose: Although gout is a relatively common condition, treatment is often not ideal with many patients continuing to experience multiple flares and some developing complications…
  • Abstract Number: 144 • 2012 ACR/ARHP Annual Meeting

    Long-Term Safety of Canakinumab in Patients with Gouty Arthritis

    Alexander So1, Reike Alten2, H. Ralph Schumacher3, Mark Bloch4, Thomas Bardin5, Markus R. John6, Gerhard Krammer6, Jan Michael Nebesky6, Aiyang Tao7 and Naomi Schlesinger8, 1Rheumatology, CHUV, Univ of Lausanne, Lausanne, Switzerland, 2Charité Univ Medicine, Berlin, Germany, 3Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4Holdsworth House Medical Practice, Sydney, Australia, 5Rheumatology, Hôpital Lariboisière, Paris, France, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ

    Background/Purpose: Gouty arthritis (GA) is a chronic inflammatory disease. Targeting the inflammatory pathway through IL-1β inhibition with canakinumab (CAN) may provide significant long-term benefits.  CAN…
  • Abstract Number: 145 • 2012 ACR/ARHP Annual Meeting

    Prevalence of Non-Gout Arthritis in Patients with Gout: Not As Sparing As Previously Thought

    Fernando Perez-Ruiz1 and Ana M. Herrero-Beites2, 1Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, 2Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain

    Background/Purpose: the presence of other chronic inflammatory disease has been historically and academically thought to be “protective” conditions for the development of gout. Objective: to…
  • Abstract Number: 146 • 2012 ACR/ARHP Annual Meeting

    The Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients with Anakinra

    Mary Bach1, Jane Park1, Pradipta Ghosh1, Peter A. Simkin2 and Gregory C. Gardner3, 1Rheumatology, University of Washington, Seattle, WA, 2Div of Rheumatology, University of Washington, Seattle, WA, 3Medicine/Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: The management of acute crystal-induced arthritis in the hospital setting may be a difficult clinical problem due to co-morbidities that limit the use of…
  • Abstract Number: 107 • 2012 ACR/ARHP Annual Meeting

    Sensitivity to Change of the Ultrasound synovitis  SONAR Score in RA Patients : Results of  the Scqm Cohort

    Pascal Zufferey1, Almut Scherer2, Hans Rudolf Ziswiler3, Giorgio Tamborrini4, Laure Brulhart5 and Burkhard Moeller6, 1Service of Rheumatology, Department of Musculoskeletal Medicine, Lausanne University Hospital, Lausanne, Switzerland, 2SCQM Foundation, Zurich, Switzerland, 3Rheumatology, Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, 4Department of Rheumatology, University Hospital, Zurich, Switzerland, 5service de Rhumatologie, Geneva, Switzerland, 6Rheumatology & Clin Immunology, Inselspital Bern, Bern, Switzerland

    Background/Purpose: Since the end of 2009, an ultrasound scoring call SONAR has been implemented for RA patients as a routine tool in the SCQM registry…
  • Abstract Number: 108 • 2012 ACR/ARHP Annual Meeting

    Disparity Between Sonographic and Clinical Criteria of Remission in Psoriasis Arthritis

    Christian Dejaco1, Rusmir Husic2, Judith Gretler3, Winfried B. Graninger4 and Josef Hermann2, 1Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, 2Rheumatology, Medical University Graz, Graz, Austria, 3Med Univ Klinik Graz, Auenbruggerplatz 15, Graz, Austria, 4Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria

    Background/Purpose: To compare ultrasound and clinical definitions of remission in psoriasis arthritis (PsA). Methods: Prospective study of 70 consecutive PsA patients [mean age 51.1 (±SD…
  • Abstract Number: 109 • 2012 ACR/ARHP Annual Meeting

    Does Joint Sonography Really Add Clinically Important Information Beyond Clinical Joint Examination?

    Miriam Gärtner1, Helga Radner2, Gabriela Supp2, Peter Mandl3, Daniel Aletaha1, Klaus P. Machold4 and Josef S. Smolen5, 1Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Rheumatology, Medical University of Vienna, Vienna, Austria, 4Internal Medicine III, Medical University of Vienna, Vienna, Austria, 5Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria

    Background/Purpose: Sonographic assessment of joint activity in patients with rheumatoid arthritis (RA) is considered to be more sensitive than the respective clinical assessment. However, this…
  • « Previous Page
  • 1
  • …
  • 2592
  • 2593
  • 2594
  • 2595
  • 2596
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology